iX Biopharma is also eligible for up to US$239 million in milestone payments upon achievement by Seelos of certain development milestones and product sales thresholds.
Pharmaceuticals company iX Biopharma has signed an exclusive license agreement with Seelos Therapeutics for its product, Wafermine.
Under terms of the agreement, iX Biopharma will receive an upfront payment of US$9 million ($12 million) to be satisfied in cash and shares.
